DV
Dividend Vision

CTOR — Citius Oncology, Inc.

Citius Oncology, Inc. (CTOR)

Total return is -97.8% over the past 2 years, 146.8 points behind SPY at 49.0%. Its deepest 1-year drawdown was 77.3%.

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies, including LYMPHIR for treating relapsed or refractory cutaneous T-cell lymphoma. The company does not currently distribute dividends. As an early-stage development-stage company, it is oriented toward investors seeking exposure to oncology drug development rather than income generation.

CTOR key facts

Asset type
Stock
Asset class
Equity
Inception date
08/12/2024
Last close
$0.91
Market cap
$64,054,748
Average volume
275000.0
Beta
3.477
Payout ratio
0.0
Forward P/E
35.5872
EPS
$-0.48